Loading clinical trials...
Loading clinical trials...
Phase I Trial of Oral Capecitabine Combined With 131I-huA33 in Patients With Metastatic Colorectal Cancer
Conditions
Interventions
Capecitabine
131I-huA33 (131-Iodine on humanised monoclonal antibody A33)
Locations
1
Australia
Ludwig Institute Oncology Unit and Tumor Targeting Program, Austin Health
Heidelberg, Victoria, Australia
Start Date
October 1, 2003
Primary Completion Date
January 3, 2008
Completion Date
August 29, 2012
Last Updated
October 10, 2022
NCT06662786
NCT06663319
NCT05239741
NCT05770102
NCT04812912
NCT06778382
Lead Sponsor
Ludwig Institute for Cancer Research
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions